Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence

• Published in: Clinical & translational oncology 2022-09, Vol.24 (9), p.1828-1830
• Main Authors: de Castro, Douglas Guedes, Teixeira, Carlos Henrique Andrade, Gondim, Guilherme Rocha Melo, Aguilar, Patrícia Bailão, Costa, Marcos André de Sá Barreto, Jorge, Thiago William Carnier, Morais Hanriot, Rodrigo de
• Format: Article
• Language: English
• Subjects: Brief Research Article; Medicine; Medicine & Public Health; Oncology
• ISSN: 1699-3055; 1699-3055
• DOI: 10.1007/s12094-022-02838-3

Purpose To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting. Methods/patients The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan–Meier and log-rank test was applied. Results After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P  = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P  = .0034). Conclusions This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.